tiprankstipranks
Trending News
More News >
Boston Scientific (BSX)
NYSE:BSX
Advertisement

Boston Scientific (BSX) AI Stock Analysis

Compare
3,570 Followers

Top Page

BSX

Boston Scientific

(NYSE:BSX)

Select Model
Select Model
Select Model
Outperform 75 (OpenAI - 4o)
Rating:75Outperform
Price Target:
$117.00
▲(19.84% Upside)
Boston Scientific's strong financial performance and positive earnings call sentiment are the primary drivers of its overall score. While technical indicators are mixed, the company's robust growth trajectory and strategic initiatives support a favorable outlook. However, the high valuation suggests caution for potential investors.
Positive Factors
Revenue Growth
Strong revenue growth indicates robust demand for Boston Scientific's products, enhancing its market position and supporting long-term financial stability.
Strategic Acquisitions
Strategic acquisitions enhance product offerings and market reach, positioning Boston Scientific for sustained growth in key therapeutic areas.
Cash Flow Management
Efficient cash flow management supports Boston Scientific's ability to invest in R&D and strategic initiatives, ensuring long-term competitiveness.
Negative Factors
Tariff Impacts
Tariff impacts can pressure margins, potentially reducing profitability and affecting Boston Scientific's competitive pricing strategy.
Supply Chain Constraints
Supply chain constraints can hinder product availability and sales growth, challenging Boston Scientific's ability to meet market demand.
Product Discontinuation
Product discontinuation can lead to financial write-offs and disrupt customer relationships, affecting Boston Scientific's market reputation and financial performance.

Boston Scientific (BSX) vs. SPDR S&P 500 ETF (SPY)

Boston Scientific Business Overview & Revenue Model

Company DescriptionBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
How the Company Makes MoneyBoston Scientific generates revenue primarily through the sale of its medical devices across multiple therapeutic areas. The company’s revenue model is primarily based on direct sales to hospitals, healthcare facilities, and clinics, as well as through partnerships with various distributors. Key revenue streams include sales from cardiovascular devices, which encompass coronary and peripheral interventions, as well as rhythm management products such as implantable cardioverter-defibrillators and pacemakers. Additionally, Boston Scientific benefits from recurring revenue through the sale of consumable products and accessories needed for procedures using their devices. The company also invests in research and development to innovate and expand its product offerings, which can lead to increased market share and revenue growth. Strategic partnerships with healthcare providers and co-development agreements with other medical technology firms further enhance its revenue potential by broadening its product portfolio and market reach.

Boston Scientific Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes revenue from different business units or product lines, highlighting which areas drive growth and where the company might be over-reliant or underperforming.
Chart InsightsBoston Scientific's Cardiology segment is experiencing robust growth, significantly contributing to the company's overall performance, driven by high demand for products like FARAPULSE and WATCHMAN. Despite challenges in the Urology segment due to supply chain issues, the company raised its full-year guidance, reflecting confidence in continued growth. The earnings call emphasized strong revenue growth and strategic investments in R&D, indicating a positive outlook despite regional challenges and product discontinuations.
Data provided by:Main Street Data

Boston Scientific Earnings Call Summary

Earnings Call Date:Jul 23, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 22, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong quarter for Boston Scientific, with significant growth across key segments such as Cardiovascular, Electrophysiology, and Asia Pacific regions. Noteworthy achievements in product launches and strategic acquisitions further bolstered the company's positive outlook. However, challenges such as the discontinuation of the ACURATE valve and tariff impacts were notable lowlights. Overall, the highlights significantly outweighed the lowlights.
Q2-2025 Updates
Positive Updates
Outperformance in Q2 2025
Total company operational sales grew 22% and organic sales grew 17%, exceeding the guidance range of 13% to 15%.
Cardiovascular Segment Success
The U.S. market grew by 31%, driven by the cardiovascular portfolio, and Cardiology sales increased by 28%.
Strong Growth in Asia Pacific
Asia Pacific saw a 15% operational growth, with Japan and China contributing significant double-digit growth.
Impressive Performance in WATCHMAN and FARAPULSE
WATCHMAN grew by 28%, and Electrophysiology sales grew by 94%, driven by the FARAPULSE launch.
Endoscopy and Neuromodulation Strength
Endoscopy grew 8% globally, and Neuromodulation sales increased by 7% with strong performance in DBS.
Successful M&A Activity
Acquisitions of SoniVie and Intera Medical to expand offerings in Interventional Cardiology and Peripheral Interventions.
Adjusted EPS Surpasses Expectations
Adjusted EPS of $0.75 grew 23%, exceeding the high end of the guidance range.
Negative Updates
Discontinuation of ACURATE Valve
Charges related to the discontinuation impacted the adjusted gross margin and resulted in inventory charges.
Challenges in Urology Segment
Urology growth was impacted by supply chain constraints and low-cost competition.
Tariff Impacts
Anticipated full-year tariff headwind of $100 million, affecting the gross margin.
Company Guidance
During the Boston Scientific Second Quarter 2025 Earnings Call, the company reported impressive financial metrics, with total company operational sales growing by 22% and organic sales by 17%, surpassing their guidance range of 13% to 15%. Adjusted earnings per share (EPS) reached $0.75, a 23% increase, exceeding the high-end guidance of $0.71 to $0.73. The adjusted operating margin was reported at 27.6%. Looking forward, Boston Scientific raised its full-year guidance for organic growth to 14% to 15% and anticipates a full-year adjusted EPS between $2.95 and $2.99, reflecting an 18% to 19% growth. Regional performance varied, with the U.S. growing 31% operationally, Europe, Middle East, and Africa (EMEA) at 2% operationally (7% excluding certain product discontinuations), and Asia Pacific growing 15% operationally. The company highlighted strong growth in specific business areas such as Urology, Endoscopy, Neuromodulation, and Cardiology, with the Cardiovascular segment notably leading the first half of 2025. Furthermore, the guidance for the third quarter of 2025 predicts an organic growth of 12% to 14% and an adjusted EPS of $0.70 to $0.72.

Boston Scientific Financial Statement Overview

Summary
Boston Scientific exhibits strong financial performance with robust revenue growth, healthy profit margins, and efficient cash management. The company maintains a stable financial position with moderate leverage, positioning it well for future growth.
Income Statement
85
Very Positive
Boston Scientific has demonstrated strong revenue growth with a 5.36% increase in TTM, supported by healthy gross and net profit margins of 63.23% and 13.53% respectively. The EBIT and EBITDA margins are robust at 18.37% and 23.67%, indicating efficient operational management. Overall, the company shows a positive growth trajectory and profitability.
Balance Sheet
78
Positive
The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.54, indicating moderate leverage. The return on equity stands at 11.49%, showcasing effective utilization of equity to generate profits. The equity ratio of 53.94% suggests a solid equity base relative to total assets, contributing to financial stability.
Cash Flow
82
Very Positive
Cash flow analysis reveals a strong free cash flow growth rate of 15.25% in TTM, highlighting improved cash generation capabilities. The operating cash flow to net income ratio of 0.83 and free cash flow to net income ratio of 0.77 indicate efficient cash conversion and healthy liquidity. Overall, cash flow management appears robust.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue18.49B16.75B14.24B12.68B11.89B9.91B
Gross Profit11.69B10.27B8.83B7.71B7.46B5.58B
EBITDA4.71B3.94B3.45B2.74B2.52B1.51B
Net Income2.50B1.85B1.59B698.00M1.04B-82.00M
Balance Sheet
Total Assets41.56B39.40B35.14B32.47B32.23B30.78B
Cash, Cash Equivalents and Short-Term Investments534.00M414.00M865.00M928.00M1.93B1.73B
Total Debt12.03B11.15B9.49B9.28B9.45B9.54B
Total Liabilities18.91B17.39B15.61B14.90B15.61B15.45B
Stockholders Equity22.42B21.77B19.28B17.57B16.62B15.33B
Cash Flow
Free Cash Flow3.31B2.65B1.70B914.00M1.32B1.13B
Operating Cash Flow4.29B3.44B2.50B1.53B1.87B1.51B
Investing Cash Flow-6.76B-5.69B-2.57B-2.01B-1.60B-411.00M
Financing Cash Flow114.00M1.81B5.00M-548.00M-95.00M293.00M

Boston Scientific Technical Analysis

Technical Analysis Sentiment
Negative
Last Price97.63
Price Trends
50DMA
103.52
Negative
100DMA
103.48
Negative
200DMA
101.01
Negative
Market Momentum
MACD
-2.03
Positive
RSI
32.79
Neutral
STOCH
40.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSX, the sentiment is Negative. The current price of 97.63 is below the 20-day moving average (MA) of 101.39, below the 50-day MA of 103.52, and below the 200-day MA of 101.01, indicating a bearish trend. The MACD of -2.03 indicates Positive momentum. The RSI at 32.79 is Neutral, neither overbought nor oversold. The STOCH value of 40.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSX.

Boston Scientific Risk Analysis

Boston Scientific disclosed 28 risk factors in its most recent earnings report. Boston Scientific reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Boston Scientific Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
$120.85B26.019.73%2.99%4.98%22.08%
79
Outperform
$232.44B16.7027.65%1.74%5.85%152.28%
75
Outperform
$141.08B48.8313.77%0.90%11.36%-15.66%
75
Outperform
$145.48B58.4311.71%21.45%36.19%
74
Outperform
$45.32B52.7039.30%-5.23%-39.83%
71
Outperform
$26.31B46.9822.21%9.30%-14.95%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BSX
Boston Scientific
97.04
12.90
15.33%
ABT
Abbott Laboratories
133.11
21.69
19.47%
DXCM
Dexcom
66.46
0.46
0.70%
EW
Edwards Lifesciences
77.19
12.09
18.57%
MDT
Medtronic
95.24
8.10
9.30%
SYK
Stryker
369.67
15.61
4.41%

Boston Scientific Corporate Events

Executive/Board Changes
Boston Scientific Announces Executive Retirement Plan Update
Neutral
Sep 4, 2025

On August 29, 2025, Boston Scientific announced that Jeffrey B. Mirviss will retire from his position as Executive Vice President and President of Peripheral Interventions, effective December 1, 2025. He will continue as a senior advisor until February 27, 2026, receiving a prorated base salary. The company plans to enter into a Retirement Agreement with Mr. Mirviss, ensuring he receives benefits consistent with the company’s Executive Retirement Plan and other incentive programs.

The most recent analyst rating on (BSX) stock is a Buy with a $116.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 12, 2025